Satoshi Kawaguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Satoshi Kawaguchi has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Il-Man Kim
Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, USA
11 shared publications Tatsuya Aonuma
Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, USA
9 shared publicationsBruno Moukette
Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, USA
6 shared publications- Suthat Liangpunsakul
Division of Gastroenterology and Hepatology, Department of Medicine Indiana University School of Medicine Indianapolis Indiana USA
6 shared publications Marisa N. Sepúlveda
Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, USA
5 shared publications- Motoi Okada
Department of Emergency Medicine Asahikawa Medical University Asahikawa Japan
5 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7656
Kidney Function Trajectories in Patients with and Without Chronic Kidney Disease Undergoing Transcatheter Aortic Valve Replacement: A Single-Retrospective Cohort Study
Background/Objectives: Transcatheter aortic valve replacement (TAVR) may improve systemic hemodynamics and kidney perfusion; however, its effect on long-term kidney function remains unclear. We evaluated kidney function trajectories before and after TAVR in patients with and without chronic kidney disease (CKD). Methods: This single-center retrospective cohort study included patients with severe aortic stenosis (AS) who underwent TAVR between June 2016 and December 2024. Overall, 314 eligible patients were classified by baseline estimated glomerular filtration rate (eGFR) as without CKD (≥60 mL/min/1.73 m2) or with CKD (2). Linear mixed-effects models estimated pre- and post-TAVR eGFR slopes, which were compared between groups after covariate adjustment. Results: Median follow-up was 2.0 years. Adjusted pre-TAVR eGFR slopes were −2.11 (95% confidence interval [CI], −3.34 to −0.89) mL/min/1.73 m2/year in patients without CKD and −2.83 (95% CI, −3.65 to −2.01) mL/min/1.73 m2/year in patients with CKD. The post-TAVR slopes were −4.02 (95% CI, −5.68 to −2.35) mL/min/1.73 m2/year in patients without CKD and −0.83 (95% CI, −2.04 to 0.39) mL/min/1.73 m2/year in patients with CKD, with a significant group difference of 3.19 (95% CI, 1.44 to 4.94) mL/min/1.73 m2/year (p < 0.001). In patients with CKD, the post-TAVR slope improved relative to the pre-TAVR slope by 2.01 (95% CI, 0.51 to 3.50) mL/min/1.73 m2/year (p < 0.01), whereas no significant change was observed in those without CKD. Conclusions: eGFR decline after TAVR was attenuated in patients with CKD compared with those without CKD, suggesting that kidney function may be preserved through hemodynamic improvement following TAVR.
- 2 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7656
Open AccessKidney Function Trajectories in Patients with and Without Chronic Kidney Disease Undergoing Transcatheter Aortic Valve Replacement: A Single-Retrospective Cohort Study
Background/Objectives: Transcatheter aortic valve replacement (TAVR) may improve systemic hemodynamics and kidney perfusion; however, its effect on long-term kidney function remains unclear. We evaluated kidney function trajectories before and after TAVR in patients with and without chronic kidney disease (CKD). Methods: This single-center retrospective cohort study included patients with severe aortic stenosis (AS) who underwent TAVR between June 2016 and December 2024. Overall, 314 eligible patients were classified by baseline estimated glomerular filtration rate (eGFR) as without CKD (≥60 mL/min/1.73 m2) or with CKD (2). Linear mixed-effects models estimated pre- and post-TAVR eGFR slopes, which were compared between groups after covariate adjustment. Results: Median follow-up was 2.0 years. Adjusted pre-TAVR eGFR slopes were −2.11 (95% confidence interval [CI], −3.34 to −0.89) mL/min/1.73 m2/year in patients without CKD and −2.83 (95% CI, −3.65 to −2.01) mL/min/1.73 m2/year in patients with CKD. The post-TAVR slopes were −4.02 (95% CI, −5.68 to −2.35) mL/min/1.73 m2/year in patients without CKD and −0.83 (95% CI, −2.04 to 0.39) mL/min/1.73 m2/year in patients with CKD, with a significant group difference of 3.19 (95% CI, 1.44 to 4.94) mL/min/1.73 m2/year (p < 0.001). In patients with CKD, the post-TAVR slope improved relative to the pre-TAVR slope by 2.01 (95% CI, 0.51 to 3.50) mL/min/1.73 m2/year (p < 0.01), whereas no significant change was observed in those without CKD. Conclusions: eGFR decline after TAVR was attenuated in patients with CKD compared with those without CKD, suggesting that kidney function may be preserved through hemodynamic improvement following TAVR.
- Open Access
- 14 September 2026
- Published by Springer Nature in Cell Death & Disease
Homeobox a4 is proapoptotic in the AC16 human cardiomyocyte cell line and a key effector of the MIAT/miR-150 axis in murine myocardial infarction
MicroRNA-150-5p (miR-150) was correlated with heart failure (HF) severity in humans. Left ventricular homeobox a4 (HOXA4) was upregulated in patients with HF. Gain-of-function mutants in myocardial infarction-associated transcript (MIAT) were associated with increased risk of myocardial infarction (MI) in humans. Our previous unbiased profiling and mechanistic studies revealed that miR-150 was a pivotal target of MIAT repression in vivo and directly repressed profibrotic HOXA4 in vitro. However, there is a paucity of detailed mechanistic insight into how the MIAT/miR-150 axis regulates HF and a deficit of definitive studies using mouse models to establish its functional relationship with key downstream targets. In this study, we determine whether HOXA4 modulates cardiomyocyte apoptosis and is functionally regulated by the MIAT/miR-150 axis in vivo. Our in vitro studies, for the first time, reveal that HOXA4 is proapoptotic and promotes apoptosis in the AC16 adult human cardiomyocyte cell line and that the protective roles of miR-150 in the AC16 adult human cardiomyocyte cell line are mediated by functional repression of HOXA4 . Moreover, Hoxa4 ablation in mice attenuates maladaptive post-MI remodeling. Significantly, we show using novel miR-150; Hoxa4 double knockout and MIAT transgenic; Hoxa4 knockout mouse models that genetic deletion of Hoxa4 blunts adverse post-MI effects caused by miR-150 loss or MIAT gain, establishing their in vivo functional relationships. These findings delineate a crucial functional link among MIAT, miR-150, and HOXA4 as a novel regulatory mechanism pertinent to cardiomyocyte apoptosis and ischemic HF. Our study will facilitate the development of new miR-150 activators and inhibitors of the MIAT/HOXA4 axis for the treatment of heart disease.
- 14 September 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessHomeobox a4 is proapoptotic in the AC16 human cardiomyocyte cell line and a key effector of the MIAT/miR-150 axis in murine myocardial infarction
MicroRNA-150-5p (miR-150) was correlated with heart failure (HF) severity in humans. Left ventricular homeobox a4 (HOXA4) was upregulated in patients with HF. Gain-of-function mutants in myocardial infarction-associated transcript (MIAT) were associated with increased risk of myocardial infarction (MI) in humans. Our previous unbiased profiling and mechanistic studies revealed that miR-150 was a pivotal target of MIAT repression in vivo and directly repressed profibrotic HOXA4 in vitro. However, there is a paucity of detailed mechanistic insight into how the MIAT/miR-150 axis regulates HF and a deficit of definitive studies using mouse models to establish its functional relationship with key downstream targets. In this study, we determine whether HOXA4 modulates cardiomyocyte apoptosis and is functionally regulated by the MIAT/miR-150 axis in vivo. Our in vitro studies, for the first time, reveal that HOXA4 is proapoptotic and promotes apoptosis in the AC16 adult human cardiomyocyte cell line and that the protective roles of miR-150 in the AC16 adult human cardiomyocyte cell line are mediated by functional repression of HOXA4 . Moreover, Hoxa4 ablation in mice attenuates maladaptive post-MI remodeling. Significantly, we show using novel miR-150; Hoxa4 double knockout and MIAT transgenic; Hoxa4 knockout mouse models that genetic deletion of Hoxa4 blunts adverse post-MI effects caused by miR-150 loss or MIAT gain, establishing their in vivo functional relationships. These findings delineate a crucial functional link among MIAT, miR-150, and HOXA4 as a novel regulatory mechanism pertinent to cardiomyocyte apoptosis and ischemic HF. Our study will facilitate the development of new miR-150 activators and inhibitors of the MIAT/HOXA4 axis for the treatment of heart disease.
- Open Access
- 16 March 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (1) , 21
MicroRNA Regulation in Kidney Interstitial Fibrosis
MicroRNAs (miRNAs) are small non-coding RNAs that play central roles in post-transcriptional gene regulation and cellular homeostasis maintenance. Dysregulation of miRNA expression is increasingly recognized as a key contributor to tissue injury during the acute phase and to disease progression in the chronic phase. Chronic kidney disease (CKD) commonly progresses and ultimately leads to kidney failure through interstitial fibrosis, which is the final common pathway of CKD progression. Interstitial fibrosis is driven not only by fibroblast activation but also by phenotypic transitions in injured tubular epithelial cells, infiltrating macrophages, and peritubular capillary cells. These multifaceted cellular pathways induce and exacerbate interstitial fibrosis, and several miRNAs have been identified as important regulators of these pathways. In addition to fibrotic pathophysiological features, disease-specific dysregulation of miRNAs has been increasingly detected in various causes of CKD, including diabetic kidney disease, chronic glomerulonephritis, and nephrosclerosis. In this review, we provide an integrated overview of miRNA-mediated regulation in CKD, with particular emphasis on cell lineage functions within fibrotic pathways and disease-specific roles. Finally, we discuss the emerging potential of miRNAs as biomarkers and therapeutic targets for CKD and highlight future research directions.
- 16 March 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (1) , 21
Open AccessMicroRNA Regulation in Kidney Interstitial Fibrosis
MicroRNAs (miRNAs) are small non-coding RNAs that play central roles in post-transcriptional gene regulation and cellular homeostasis maintenance. Dysregulation of miRNA expression is increasingly recognized as a key contributor to tissue injury during the acute phase and to disease progression in the chronic phase. Chronic kidney disease (CKD) commonly progresses and ultimately leads to kidney failure through interstitial fibrosis, which is the final common pathway of CKD progression. Interstitial fibrosis is driven not only by fibroblast activation but also by phenotypic transitions in injured tubular epithelial cells, infiltrating macrophages, and peritubular capillary cells. These multifaceted cellular pathways induce and exacerbate interstitial fibrosis, and several miRNAs have been identified as important regulators of these pathways. In addition to fibrotic pathophysiological features, disease-specific dysregulation of miRNAs has been increasingly detected in various causes of CKD, including diabetic kidney disease, chronic glomerulonephritis, and nephrosclerosis. In this review, we provide an integrated overview of miRNA-mediated regulation in CKD, with particular emphasis on cell lineage functions within fibrotic pathways and disease-specific roles. Finally, we discuss the emerging potential of miRNAs as biomarkers and therapeutic targets for CKD and highlight future research directions.
- Open Access
- 13 March 2026
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 41 (3) , 852-853
Capsule deformation of a self‑expandable transcatheter aortic valve caused by repeated valve captures
- 13 March 2026
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 41 (3) , 852-853
Open AccessCapsule deformation of a self‑expandable transcatheter aortic valve caused by repeated valve captures
- Open Access
- 28 February 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
BACH2 links β1-adrenergic receptor/β-arrestin1 signaling to MIAT to inhibit cardiac fibroblast activation and cardiomyocyte apoptosis
The myocardial infarction-associated transcript (MIAT), a conserved long noncoding RNA, is upregulated in failing human and murine hearts. We previously demonstrated that systemic or cardiomyocyte (CM)-restricted ablation of MIAT in mice attenuated maladaptive cardiac remodeling following myocardial infarction by suppressing the expression of proapoptotic and profibrotic genes. Despite growing evidence from human and rodent studies implicating MIAT in heart failure, the upstream regulatory pathways controlling its expression remain poorly defined. We hypothesized that MIAT is regulated either by β-arrestin1-mediated β 1 -adrenergic receptor protective signaling or by the transcription factor BTB domain and CNC homolog 2 (BACH2), which is downregulated in failing human and murine hearts. In this study, we show that treatment with the β-blocker carvedilol downregulates cardiac MIAT via β 1 -adrenergic receptor/β-arrestin1 signaling and concurrently upregulates BACH2. Mechanistically, our co-immunoprecipitation and electrophoretic mobility shift assays reveal that BACH2 forms a nuclear complex with β-arrestin1 and binds to conserved elements within the MIAT promoter. Using primary adult human cardiac fibroblasts (CFs) as well as human and rodent CMs, we further show that BACH2 represses profibrotic and proapoptotic MIAT expression, thereby inhibiting CF activation and CM apoptosis. Together, these findings identify a novel regulatory axis involving β 1 -adrenergic receptor/β-arrestin1 signaling, BACH2, and MIAT, highlighting its critical role in maladaptive cardiac remodeling.
- 28 February 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Open AccessBACH2 links β1-adrenergic receptor/β-arrestin1 signaling to MIAT to inhibit cardiac fibroblast activation and cardiomyocyte apoptosis
The myocardial infarction-associated transcript (MIAT), a conserved long noncoding RNA, is upregulated in failing human and murine hearts. We previously demonstrated that systemic or cardiomyocyte (CM)-restricted ablation of MIAT in mice attenuated maladaptive cardiac remodeling following myocardial infarction by suppressing the expression of proapoptotic and profibrotic genes. Despite growing evidence from human and rodent studies implicating MIAT in heart failure, the upstream regulatory pathways controlling its expression remain poorly defined. We hypothesized that MIAT is regulated either by β-arrestin1-mediated β 1 -adrenergic receptor protective signaling or by the transcription factor BTB domain and CNC homolog 2 (BACH2), which is downregulated in failing human and murine hearts. In this study, we show that treatment with the β-blocker carvedilol downregulates cardiac MIAT via β 1 -adrenergic receptor/β-arrestin1 signaling and concurrently upregulates BACH2. Mechanistically, our co-immunoprecipitation and electrophoretic mobility shift assays reveal that BACH2 forms a nuclear complex with β-arrestin1 and binds to conserved elements within the MIAT promoter. Using primary adult human cardiac fibroblasts (CFs) as well as human and rodent CMs, we further show that BACH2 represses profibrotic and proapoptotic MIAT expression, thereby inhibiting CF activation and CM apoptosis. Together, these findings identify a novel regulatory axis involving β 1 -adrenergic receptor/β-arrestin1 signaling, BACH2, and MIAT, highlighting its critical role in maladaptive cardiac remodeling.
- Open Access
- 23 February 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (3)
Hidden Drug Rash With Eosinophilia and Systemic Symptoms ( DRESS ): A Rare Case of Preceding Organ Damage Before Skin Manifestations
Drug rash with eosinophilia and systemic symptoms (DRESS) is a drug‐induced hypersensitivity reaction that can cause significant organ injury. Unlike anaphylaxis, it often goes unnoticed because the skin eruptions develop slowly. We report the case of a 75‐year‐old woman who presented with eosinophilia and acute kidney injury. Two weeks earlier, she had been treated with minocycline hydrochloride for a giant liver cyst. No rash was initially observed, but by the third day of admission, a widespread eruption appeared. She was diagnosed with minocycline‐induced DRESS and treated with oral prednisolone, which was tapered after hemodialysis was discontinued. She was later transferred back to her previous hospital for rehabilitation. This case highlights that many drugs can trigger DRESS syndrome and that serious organ damage may precede the onset of rash. Clinicians should remain alert to this possibility when evaluating patients with unexplained organ dysfunction.
- 23 February 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (3)
Open AccessHidden Drug Rash With Eosinophilia and Systemic Symptoms ( DRESS ): A Rare Case of Preceding Organ Damage Before Skin Manifestations
Drug rash with eosinophilia and systemic symptoms (DRESS) is a drug‐induced hypersensitivity reaction that can cause significant organ injury. Unlike anaphylaxis, it often goes unnoticed because the skin eruptions develop slowly. We report the case of a 75‐year‐old woman who presented with eosinophilia and acute kidney injury. Two weeks earlier, she had been treated with minocycline hydrochloride for a giant liver cyst. No rash was initially observed, but by the third day of admission, a widespread eruption appeared. She was diagnosed with minocycline‐induced DRESS and treated with oral prednisolone, which was tapered after hemodialysis was discontinued. She was later transferred back to her previous hospital for rehabilitation. This case highlights that many drugs can trigger DRESS syndrome and that serious organ damage may precede the onset of rash. Clinicians should remain alert to this possibility when evaluating patients with unexplained organ dysfunction.
- Open Access
- 16 January 2026
- Published by MDPI AG in Preprints.org
MicroRNA Regulation in Renal Interstitial Fibrosis
MicroRNAs (miRNAs) are small non-coding RNAs that play central roles in post-transcriptional gene regulation and cellular homeostasis maintenance. Dysregula-tion of miRNA expression is increasingly recognized as a key contributor to tissue injury during the acute phase and to disease progression in the chronic phase. Chronic kidney disease (CKD) commonly progresses and ultimately leads to kidney failure through interstitial fibrosis, which is the final common pathway of CKD progression. Interstitial fibrosis is driven not only by fibroblast activation but also by a phenotypic transition of injured tubular epithelial cells, infiltrating macrophages, and peritubular capillary cells. These multifaceted cellular pathways induce and exacerbate interstitial fibrosis, and several miRNAs have been identified as important regulators of these pathways. In addition to fibrotic pathophysiological features, disease-specific dysregulation of miRNAs has been increasingly detected in various causes of CKD, including diabetic kidney disease, chronic glomerulonephritis, and nephrosclerosis. In this review, we provide an integrated overview of miRNA-mediated regulation in CKD, with particular emphasis on cell lineage functions within fibrotic pathways and disease-specific roles. Finally, we discuss the emerging potential of miRNAs as biomarkers and therapeutic targets for CKD and highlight future research directions.
- 16 January 2026
- Published by MDPI AG in Preprints.org
Open AccessMicroRNA Regulation in Renal Interstitial Fibrosis
MicroRNAs (miRNAs) are small non-coding RNAs that play central roles in post-transcriptional gene regulation and cellular homeostasis maintenance. Dysregula-tion of miRNA expression is increasingly recognized as a key contributor to tissue injury during the acute phase and to disease progression in the chronic phase. Chronic kidney disease (CKD) commonly progresses and ultimately leads to kidney failure through interstitial fibrosis, which is the final common pathway of CKD progression. Interstitial fibrosis is driven not only by fibroblast activation but also by a phenotypic transition of injured tubular epithelial cells, infiltrating macrophages, and peritubular capillary cells. These multifaceted cellular pathways induce and exacerbate interstitial fibrosis, and several miRNAs have been identified as important regulators of these pathways. In addition to fibrotic pathophysiological features, disease-specific dysregulation of miRNAs has been increasingly detected in various causes of CKD, including diabetic kidney disease, chronic glomerulonephritis, and nephrosclerosis. In this review, we provide an integrated overview of miRNA-mediated regulation in CKD, with particular emphasis on cell lineage functions within fibrotic pathways and disease-specific roles. Finally, we discuss the emerging potential of miRNAs as biomarkers and therapeutic targets for CKD and highlight future research directions.
- Open Access
- 25 July 2025
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 10 (8) , 101330
Periostin is a Pivotal Target of microRNA-150-5p in Cardiac Fibroblast Activation and Chronic Myocardial Infarction
- 25 July 2025
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 10 (8) , 101330
Open AccessPeriostin is a Pivotal Target of microRNA-150-5p in Cardiac Fibroblast Activation and Chronic Myocardial Infarction
- Open Access
- 20 February 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-11
Cardiomyocyte-restricted MIAT deletion is sufficient to protect against murine myocardial infarction
Myocardial infarction-associated transcript (MIAT), an intergenic long noncoding RNA (lncRNA), is conserved between rodents and humans and is directly linked to maladaptive cardiac remodeling in both patients and mouse models with various forms of heart failure (HF). We previously reported attenuation of cardiac stress, apoptosis, and fibrosis in a murine model of myocardial infarction (MI) with global MIAT ablation. Our transcriptomic profiling and mechanistic studies further revealed MIAT-induced activation of maladaptive genes, such as Hoxa4, Fmo2, Lrrn4, Marveld3, and Fat4. However, the source of MIAT and its contribution to MI and HF remain unknown. In this study, we generate a novel cardiomyocyte (CM)-specific MIAT conditional knockout mouse model, which exhibits improved cardiac function after MI. We further report that CM-specific MIAT ablation is sufficient to reduce cardiac damage, apoptosis, and fibrosis following chronic MI. Mechanistically, CM-specific MIAT deletion in mice leads to decreased expression of proapoptotic and pathological profibrotic genes, such as p53, Bak1, Col3a1, Col6a1, Postn, and Snail1 after chronic MI. These results enable us to begin to dissect cell-specific contributions to MIAT signaling and bolster the idea that MIAT plays a direct pathological role in CMs after MI.
- 20 February 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-11
Open AccessCardiomyocyte-restricted MIAT deletion is sufficient to protect against murine myocardial infarction
Myocardial infarction-associated transcript (MIAT), an intergenic long noncoding RNA (lncRNA), is conserved between rodents and humans and is directly linked to maladaptive cardiac remodeling in both patients and mouse models with various forms of heart failure (HF). We previously reported attenuation of cardiac stress, apoptosis, and fibrosis in a murine model of myocardial infarction (MI) with global MIAT ablation. Our transcriptomic profiling and mechanistic studies further revealed MIAT-induced activation of maladaptive genes, such as Hoxa4, Fmo2, Lrrn4, Marveld3, and Fat4. However, the source of MIAT and its contribution to MI and HF remain unknown. In this study, we generate a novel cardiomyocyte (CM)-specific MIAT conditional knockout mouse model, which exhibits improved cardiac function after MI. We further report that CM-specific MIAT ablation is sufficient to reduce cardiac damage, apoptosis, and fibrosis following chronic MI. Mechanistically, CM-specific MIAT deletion in mice leads to decreased expression of proapoptotic and pathological profibrotic genes, such as p53, Bak1, Col3a1, Col6a1, Postn, and Snail1 after chronic MI. These results enable us to begin to dissect cell-specific contributions to MIAT signaling and bolster the idea that MIAT plays a direct pathological role in CMs after MI.
- Open Access
- 22 December 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (12) , 1650
MicroRNA-150 Deletion from Adult Myofibroblasts Augments Maladaptive Cardiac Remodeling Following Chronic Myocardial Infarction
MicroRNA (miR: small noncoding RNA)-150 is evolutionarily conserved and is downregulated in patients with diverse forms of heart failure (HF) and in multiple mouse models of HF. Moreover, miR-150 is markedly correlated with the outcome of patients with HF. We previously reported that systemic or cardiomyocyte-derived miR-150 in mice elicited myocardial protection through the inhibition of cardiomyocyte death, without affecting neovascularization and T cell infiltration. Our mechanistic studies also showed that the protective roles of miR-150 in ischemic mouse hearts and human cardiac fibroblasts were, in part, attributed to the inhibition of fibroblast activation via the repression of multiple profibrotic genes. However, the extent to which miR-150 expression in adult myofibroblasts (MFs) modulates the response to myocardial infarction (MI) remains unknown. Here, we develop a novel 4-hydroxytamoxifen-inducible MF-specific miR-150 conditional knockout mouse model and demonstrate that the mouse line exhibits worse cardiac dysfunction after MI. Our studies further reveal that miR-150 ablation selectively in adult MFs exacerbates cardiac damage and apoptosis after chronic MI. Lastly, MF-specific miR-150 deletion in adult mice promotes the expression of proinflammatory and profibrotic genes as well as cardiac fibrosis following chronic MI. Our findings indicate a key protective role for MF-derived miR-150 in modulating post-MI responses.
- 22 December 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (12) , 1650
Open AccessMicroRNA-150 Deletion from Adult Myofibroblasts Augments Maladaptive Cardiac Remodeling Following Chronic Myocardial Infarction
MicroRNA (miR: small noncoding RNA)-150 is evolutionarily conserved and is downregulated in patients with diverse forms of heart failure (HF) and in multiple mouse models of HF. Moreover, miR-150 is markedly correlated with the outcome of patients with HF. We previously reported that systemic or cardiomyocyte-derived miR-150 in mice elicited myocardial protection through the inhibition of cardiomyocyte death, without affecting neovascularization and T cell infiltration. Our mechanistic studies also showed that the protective roles of miR-150 in ischemic mouse hearts and human cardiac fibroblasts were, in part, attributed to the inhibition of fibroblast activation via the repression of multiple profibrotic genes. However, the extent to which miR-150 expression in adult myofibroblasts (MFs) modulates the response to myocardial infarction (MI) remains unknown. Here, we develop a novel 4-hydroxytamoxifen-inducible MF-specific miR-150 conditional knockout mouse model and demonstrate that the mouse line exhibits worse cardiac dysfunction after MI. Our studies further reveal that miR-150 ablation selectively in adult MFs exacerbates cardiac damage and apoptosis after chronic MI. Lastly, MF-specific miR-150 deletion in adult mice promotes the expression of proinflammatory and profibrotic genes as well as cardiac fibrosis following chronic MI. Our findings indicate a key protective role for MF-derived miR-150 in modulating post-MI responses.